Pegcetacoplan PNH Long-Term Extension Study Completes Primary Phase

By Hipa.ai Research · November 29, 2025

Synced daily from openFDA and ClinicalTrials.gov. Last sync: June 12, 2026.

The primary completion of the Phase 3 extension study for pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH) occurred on November 29, 2025. This study, officially titled "Pegcetacoplan Long Term Safety and Efficacy Extension Study," is designed to gather extensive long-term data on the drug's profile.

Background

Pegcetacoplan is an intervention investigated for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). For chronic conditions like PNH, extension studies are particularly important as they provide crucial insights into the long-term safety and sustained efficacy of treatments over extended periods, which is vital for patient management.

Trial design

The "Pegcetacoplan Long Term Safety and Efficacy Extension Study" (NCT03531255) is a Phase 3, open-label, non-randomized, multi-center extension study. It enrolled 160 participants, all diagnosed with Paroxysmal Nocturnal Hemoglobinuria (PNH). The study involves intervention with pegcetacoplan. A key aspect of this extension study is that all eligible subjects had previously completed an earlier pegcetacoplan study, indicating a continuation of treatment for a specific patient cohort to monitor long-term outcomes.

What this means

The primary completion of this Phase 3 extension study marks a significant milestone in the ongoing evaluation of pegcetacoplan for PNH. While specific outcome data from this primary completion event are not yet available, such studies are fundamental for collecting comprehensive long-term safety and efficacy information. This data is essential for clinicians and patients to understand the sustained benefits and potential risks of pegcetacoplan over extended treatment periods, particularly for managing a chronic and complex condition like PNH.

Source

The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT03531255, titled "Pegcetacoplan Long Term Safety and Efficacy Extension Study," was posted on November 29, 2025, on clinicaltrials.gov.